Conjugate Or Complex Includes Bacterium Or Component Thereof Or Substance Produced By Said Bacterium Patents (Class 424/197.11)
-
Patent number: 6794368Abstract: The present invention relates to a composition and method useful for regulating cell proliferation and cell death in a multicellular organism. The present invention particularly relates to a composition comprising a bacterial DNA (B-DNA) and a first pharmaceutically acceptable carrier, wherein the B-DNA induces a response in responsive cells of an animal. The present invention more particularly relates to a composition comprising a mycobacterial DNA (M-DNA) and a first pharmaceutically acceptable carrier, wherein the M-DNA inhibits proliferation of responsive cells of an animal, induces apoptosis in responsive cells of an animal, and stimulattes responsive cells of the immune system of an animal to produce bioactive molecules. Methods of making the M-DNA composition and methods of using the M-DNA composition also are disclosed.Type: GrantFiled: January 10, 2002Date of Patent: September 21, 2004Assignee: Bioniche Life Sciences Inc.Inventors: Nigel C. Phillips, Mario C. Filion
-
Patent number: 6787144Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide or an antibody thereto.Type: GrantFiled: November 28, 2000Date of Patent: September 7, 2004Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6787143Abstract: The invention provides compositions and methods for treatment of amyloidogenic diseases. Such methods entail administering an agent that induces a beneficial immune response against an amyloid deposit in the patient. The methods are particularly useful for prophylactic and therapeutic treatment of Alzheimer's disease. In such methods, a suitable agent is A&bgr; peptide or an antibody thereto.Type: GrantFiled: November 28, 2000Date of Patent: September 7, 2004Assignee: Neuralab LimitedInventor: Dale B. Schenk
-
Patent number: 6783764Abstract: The present invention relates to live attenuated bacteria of the genus Actinobacillus pleuropneumoniae that have a mutation in an apxIV gene such that no functional ApxIV toxin can be produced. The invention also relates to methods for the production of such bacteria. Also vaccines comprising such bacteria and methods for the production of such vaccines are part of the invention. The invention further relates to subunit vaccines comprising an ApxIV toxin, to methods for the production of such vaccines and to methods for the protection of animals against infection with bacteria of the genus Actinobacillus pleuropneumoniae. In addition, the invention relates to the promotor of the apxIV gene. Finally, the invention relates to diagnostic test for the selective diagnosis of Actinobacillus pleuropneumoniae infections and to diagnostic tests discriminating between Actinobacillus pleuropneumoniae field strains and vaccine strains.Type: GrantFiled: August 31, 1999Date of Patent: August 31, 2004Assignee: Akzo Nobel NVInventors: Ruud Philip Antoon Maria Segers, Joachim Frey
-
Patent number: 6773707Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: August 10, 2000Date of Patent: August 10, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Patent number: 6764686Abstract: This invention relates to modified pneumolysin polypeptides that retain the immunogenic nature of pneumolysin but have reduced or undetectable hemolytic activity compared to native pneumolysin. The invention also provides a method for generating novel pneumolysin variants with these desired characteristic properties. The invention also provides immunogenic compositions useful as pharmaceutical compositions including vaccines in which non-toxic, modified pneumolysin is used to stimulate protective immunity against Streptococcus pneumoniae. The vaccines may be compositions in which the modified pneumolysin is conjugated to bacterial polysaccharides or may be carried on an attenuated viral vector.Type: GrantFiled: July 21, 1998Date of Patent: July 20, 2004Assignee: Baxter International Inc.Inventors: Conceicao Minetti, Francis Michon, Jeffrey K. Pullen, Mary Ellen Polvino-Bodnar, Shu-Mei Liang, Joseph Y. Tai
-
Patent number: 6761892Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: April 20, 2000Date of Patent: July 13, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz-Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takechi, Mark Mayhew
-
Patent number: 6756040Abstract: The invention relates to a vaccine formulation for the prevention of Haemophilus Influenzae Type B (Hib) infections and where the antigen is adsorbed onto aluminum phosphate. The invention also relates to a multivalent vaccines, that is a vaccine for the amelioration or treatment of more than one disease states. The present invention also relates to the production and use of such vaccines in medicine.Type: GrantFiled: May 23, 2002Date of Patent: June 29, 2004Assignee: SmithKline Beecham Biologicals s.a.Inventors: Julien Peetermans, Pierre Hauser
-
Patent number: 6756361Abstract: A majority of E. faecalis and E. faecium clinical isolates fall into two groups and three groups, respectively. Distinct antigens are associate with each of the five groups. The Enterococcus antigens are readily obtained from strains of E. faecalis and E. faecium, and can elicit production of protective antibodies. Accordingly, the antigens are useful for vaccines which protect against infection by clinically significant (pathogenic) Enterococcus isolates. The antigens and antibodies generated to the antigens are also useful in diagnostic assays.Type: GrantFiled: October 14, 1997Date of Patent: June 29, 2004Assignee: NABIInventors: Ali Ibrahim Fattom, Ramesh K. Sood, Sara E. Shepherd
-
Patent number: 6719974Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: October 5, 2000Date of Patent: April 13, 2004Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
-
Patent number: 6685949Abstract: A conjugate vaccine for Moraxella (Branhamella) catarrhalis comprising isolated lipooligosaccharide from which esterified fatty acids have been removed, to produce a detoxified lipooligosaccharide (dLOS), or from which lipid A has been removed, to produce a detoxified oligosaccharide (OS), which is linked to an immunogenic carrier. The vaccine is useful for preventing otitis media and respiratory infections caused by M. catarrhalis in mammals, including humans.Type: GrantFiled: July 5, 2000Date of Patent: February 3, 2004Assignee: The United States of America as represented by the Department of Health & Human ServicesInventors: Xin-Xing Gu, John B. Robbins
-
Patent number: 6676945Abstract: Mycobacterium tuberculosis protein having a molecular weight of 28.779 Da, and hybrid proteins containing at least portions of its sequence. These proteins may in particular be used in vaccines or for the detection of specific tuberculosis antibodies.Type: GrantFiled: November 2, 2001Date of Patent: January 13, 2004Assignee: Institut PasteurInventors: Anne Laqueyrerie, Gilles Marchal, Pascale Pescher, Felix Romain
-
Patent number: 6673905Abstract: A method is provided for covalently linking carbohydrates, proteins, nucleic acids, and other biomolecules under neutral conditions, using a Diels-Alder cycloaddition reaction. In an example, activated carbon-carbon double bonds were attached to free amino sites of a carrier protein, and a conjugated diene was attached to a carbohydrate hapten. Spontaneous coupling of the carbohydrate and the protein components under very mild conditions provided glycoconjugates containing up to 37 carbohydrate hapten units per carrier protein molecule. The method is also applicable to the immobilization of biomolecules on gel or solid supports. The conjugated products are useful as immunogens and as analytical and diagnostic reagents.Type: GrantFiled: August 1, 2001Date of Patent: January 6, 2004Assignee: The United States of America as represented by the Department of Health and Human ServicesInventor: Vince Pozsgay
-
Patent number: 6670322Abstract: A method of targeting therapeutic molecules to motor neurons is disclosed. In one embodiment, this method comprises the steps of (a) synthesizing a prodrug comprising a therapeutic molecule covalently bound to a polymeric delivery vehicle, and (b) conjugating the prodrug to a botulinum neurotoxin heavy chain.Type: GrantFiled: May 30, 2001Date of Patent: December 30, 2003Assignee: Wisconsin Alumni Research FoundationInventors: Michael C. Goodnough, Eric A. Johnson, William H. Tepp, Carl J. Malizio
-
Patent number: 6663868Abstract: The present invention relates to methods and compositions for inducing an immune response in a subject, wherein the subject is administered an effective amount of a heat shock protein complexed to a hybrid antigen comprising an antigenic domain and a heat shock protein-binding domain. These methods and compositions may be used in the treatment of infectious diseases and cancers.Type: GrantFiled: February 13, 1998Date of Patent: December 16, 2003Assignee: Sloan-Kettering Institute for Cancer ResearchInventors: James E. Rothman, Franz Ulrich Hartl, Mee H. Hoe, Alan Houghton, Yoshizumi Takeuchi, Mark Mayhew
-
Patent number: 6656472Abstract: Multivalent immunogenic molecules comprise a carrier molecule containing at least one functional T-cell epitope and multiple different carbonhydrate fragments each linked to the carrier molecule and each containing at least one functional B-cell epitope. The carrier molecule inparts enhanced immunogenicity to the multiple carbohydrate fragments. The carbohydrate fragments may be capsular oligosaccharide fragments from Streptococcus pneumoniae which may be serotypes (1, 4, 5, 6B, 9V, 14, 18C, 19F or 23F), or Neisseria meningitidis, which may be serotype (A, B, C) W-135 or Y. Such oligosaccharide fragments may be sized from about 2 to about 5 kDa. Alternatively, the carbohydrate fragments may be fragments of carbohydrate-based tumor antigens, such as Globo H, LeY or STn. The multivalent molecules may be produced by random conjugation or site-directed conjugation of the carbohydrate fragments to the carrier molecule.Type: GrantFiled: December 22, 2000Date of Patent: December 2, 2003Assignee: Aventis Pasteur LimitedInventors: Pele Chong, Alf Lindberg, Michel H. Klein
-
Patent number: 6656477Abstract: A protein derivable from Actinobacillus pleuropneumoniae (APP) having a molecular size ranging between 43 Kd on SDS PAGE is described. The protein is soluble on sodium lauryl sarcosinate (SLS) and not heat modifiable. The protein can also be derived by recombinant methods. The protein in a vaccine provides immunity against multiple serotypes of APP.Type: GrantFiled: July 28, 1992Date of Patent: December 2, 2003Assignee: Board of Trustees of Michigan State UniversityInventors: Martha H. Mulks, Brad J. Thacker, Maria Wilma T. Cruz
-
Patent number: 6649171Abstract: The invention provides BASB021 polypeptides and polynucleotides encoding BASB021 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: December 8, 2000Date of Patent: November 18, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventor: Joelle Thonnard
-
Patent number: 6645503Abstract: Antigenic conjugates are provided which comprise a carrier protein covalently bonded to the conserved portion of a lipopolysaccharide of a gram negative bacteria, wherein the conserved portion of the lipopolysaccharide comprises the inner core and lipid A portions of the lipopolysaccharide, the conjugate eliciting a cross reactive immune response against heterologous strains of the gram negative bacteria.Type: GrantFiled: March 9, 1999Date of Patent: November 11, 2003Assignee: Wyeth Holdings CorporationInventors: Rasappa G. Arumugham, Maria Fortuna-Nevin, Michael A. Apicella, Bradford W. Gibson
-
Patent number: 6638513Abstract: The present invention pertains generally to Neisseria meningitidis serogroup B glycoconjugates. More particularly, the invention pertains to glycoconjugates formed from a Neisseria meningitidis serogroup B capsular oligosaccharide derivative (MenB OS derivative) in which sialic acid residue N-acetyl groups are replaced with N-acyl groups. The invention also pertains to vaccine formulations containing the glycoconjugates, methods of making the vaccine formulations, and methods of using the vaccine formulations to treat or prevent Neisseria meningitidis serogroup B or E. coli K1 disease in a mammalian subject.Type: GrantFiled: August 7, 1997Date of Patent: October 28, 2003Assignee: Chiron S.r.l.Inventor: Robert Seid
-
Patent number: 6632439Abstract: The present invention relates to a method of producing a vaccine for the prevention of F. necrophorum bacterial infections, comprising isolating the F. necrophorum bacteria from a bovine species, growing the bacteria in a suitable growth medium for a period equal to between about 10 hours and about 18 hours so as to achieve a bacterial population equal to at least 1×105 CFU/ml, terminating the growth, and using a whole cell culture to form the vaccine. Additionally, the present invention relates to the vaccine comprised of a killed whole cell population of the F. necrophorum bacteria taken from a bovine. The present invention further relates to a method for preventing footrot and liver abscesses caused by F. necrophorum bacteria.Type: GrantFiled: September 29, 1999Date of Patent: October 14, 2003Assignee: Novartis Animal Health, Inc.Inventors: Adrian Liem, Gary A. Anderson, Douglas L. Stine
-
Patent number: 6632437Abstract: The present invention relates to a polysaccharide-protein conjugate. The invention also relates to a method of using the conjugate to prevent systemic infections. The invention further relates to a pharmaceutical composition. The invention also relates to a method of producing a polysaccharide-protein conjugate.Type: GrantFiled: November 15, 1993Date of Patent: October 14, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Rachel Schneerson, John B. Robbins, J. N. Sarvamangala Devi
-
Patent number: 6627202Abstract: This invention relates to hepatitis B virus (“HBV”) core antigen particles that are characterized by multiple immunogen specificities. More particularly, the invention relates to HBV cote antigen particles comprising immunogens, epitopes, or other related structures, crosslinked thereto by ligands which are HBV capsid-binding peptides that selectively bind to HBV core protein. Such particles may be used as delivery systems for a diverse range of immunogenic epitopes, including the HBV capsid-binding peptides, which advantageously also inhibit and interfere with HBV viral assembly by blocking the interaction between HBV core protein and HBV surface proteins. Mixtures of different immunogens and/or capsid-binding peptide ligands may be crosslinked to the same HBV core particle. Such resulting multicomponent or multivalent HBV core particles may be advantageously used in therapeutic and prophylactic vaccines and compositions, as well as in diagnostic compositions and methods using them.Type: GrantFiled: June 4, 2001Date of Patent: September 30, 2003Assignee: Biogen, Inc.Inventor: Kenneth Murray
-
Patent number: 6627204Abstract: The invention provides BASB033 polypeptides and polynucleotides encoding BASB033 polypeptides and methods for producing such polypeptides by recombinant techniques. Also provided are diagnostic, prophylactic and therapeutic uses.Type: GrantFiled: July 18, 2001Date of Patent: September 30, 2003Assignee: SmithKline Beecham Biologicals s.a.Inventor: Jean-Louis Ruelle
-
Patent number: 6620415Abstract: Methods for treating a movement disorder by intracranial administration to a human patient of a therapeutically effective amount of a neurotoxin, such as a botulinum toxin type A.Type: GrantFiled: July 11, 2001Date of Patent: September 16, 2003Assignee: Allergan, Inc.Inventor: Stephen Donovan
-
Patent number: 6613336Abstract: Disclosed is an H. influenzae type b polysaccharide-meningococcal outer membrane protein conjugate, pharmaceutical compositions thereof, and the use thereof to induce an immune response to H. influenzae in an animal.Type: GrantFiled: May 10, 2002Date of Patent: September 2, 2003Assignee: Baxter International Inc.Inventors: Milan S. Blake, Francis Michon, Peter C. Fusco, Iver Heron
-
Patent number: 6602508Abstract: The process for depolymerizing Group B Types II and III streptococcal polysaccharide is disclosed which results in polysaccharide fragments having a reducing end suitable for conjugating to protein. Conjugate molecules, vaccines and their use to immunize mammals including humans are also disclosed.Type: GrantFiled: May 18, 2001Date of Patent: August 5, 2003Assignee: Baxter International Inc.Inventors: Francis Michon, Catherine Uitz, Joseph Y. Tai
-
Patent number: 6596283Abstract: The invention relates to chemically-modified group B polysaccharides of Neisseria meningitidis. The invention also provides vaccines in which the respective modified polysaccharides are conjugated to a protein carrier, and the like. More specifically, the present invention provides novel group B meningococcal unsaturated N-acyl derivative polysaccharides, novel conjugates of the group B meningococcal unsaturated N-acyl derivative polysaccharides, pharmaceutical compositions comprising conjugate molecules of group B meningococcal unsaturated N-acyl derivative polysaccharide fragments covalently bound to proteins, and the use of these compositions as vaccines.Type: GrantFiled: July 20, 2001Date of Patent: July 22, 2003Assignee: National Research Council of CanadaInventors: Harold J. Jennings, Robert Pon, Michele Lussier, Francis Michon
-
Patent number: 6596278Abstract: An immunological response potentiation process is disclosed for synthetic or genetically engineered antigens having low immunogenicity. The antigen is embedded into biodegradable microparticles, and the antigen-loaded microparticles are dispersed in a biodegradable medium. When parenterally administered, the antigen-loaded microparticles trigger a potentiated antibody, TH-lymphocyte and Tc-lymphocyte response, as compared to an aqueous antigen solution. The extent of immunological potentiation is at least comparable with that attained by Incomplete Freund's adjuvant compositions. Linear B-TH-cell epitopes, linear Tc-cell epitopes, dimers and multimers of those epitopes, and mixtures thereof, are used as low immunogenicity antigens. The microparticles are based on biodegradable biopolymers such as polyester, polyanhydride, and polyorthoester.Type: GrantFiled: October 11, 1995Date of Patent: July 22, 2003Assignee: RMF Dictagene S.A.Inventors: Bruno Gander, Giampietro Corradin, Ying Men, Claudio Thomasin, Hans Peter Merkle
-
Patent number: 6592872Abstract: The present invention provides a vaccine for inducing an immune response in mammal to a specific antigen, where the vaccine comprises a unit dose of a binary, cytotoxic T lymphocyte vaccine comprising an anthrax protective antigen and a full length protein antigen bound to a nontoxic anthrax protective antigen binding protein comprising at least about the first 250 amino acid residues of the lethal factor of Bacillus anthracis and less than all of the amino acid residues of the lethal factor. The present invention also provides a method of immunizing a mammal against an antigen using the vaccine, and a method of inducing antigen-presenting mammalian cells to present specific antigens via the MHC class I processing pathway.Type: GrantFiled: September 15, 1997Date of Patent: July 15, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Kurt Klimpel, Theresa J. Goletz, Naveen Arora, Stephen H. Leppla, Jay A. Berzofsky
-
Immunotherapeutic agent for cancer containing nucleoidal component of bacterium as active ingredient
Patent number: 6593096Abstract: An agent for cancer immunotherapy with independent use, containing bacterial components as an active ingredient, which induces cancer patients to exhibit immune responsiveness, as indicated by the increase of interferon-&ggr; and CD28 markers in peripheral blood, when administered to an immuno-competent patient intracutaneously.Type: GrantFiled: December 20, 1999Date of Patent: July 15, 2003Inventors: Akira Hayashi, Ichiro Azuma, Kumao Toyoshima -
Patent number: 6585981Abstract: The present invention provides a live temperature-sensitive vaccine for Mycoplasma hyopneumoniae. The present invention also provides methods of vaccinating a swine against colonization or infection of Mycoplasma hyopneumoniae.Type: GrantFiled: July 27, 2000Date of Patent: July 1, 2003Assignee: Regents of the University of MinnesotaInventor: Carlos Pijoan
-
Patent number: 6585973Abstract: A method of preparing conjugate vaccines by adsorbing a protein to a solid phase adjuvant, and covalently linking a carbohydrate to the adsorbed protein. Alternatively, the carbohydrate is first adsorbed to the solid phase adjuvant, then the protein is covalently linked to the carbohydrate. The carbohydrate may be chemically activated. Unconjugated protein may be present.Type: GrantFiled: October 28, 1999Date of Patent: July 1, 2003Assignee: Henry M. Jackson Foundation for The Advancement of Military MedicineInventor: Andrew Lees
-
Patent number: 6582699Abstract: A vaccine comprising a combination of Brucella “A” and “M” outer-polysaccharides (OPSs) and “R” protein antigens for enhancing immunity against brucellosis is disclosed. The OPS may be obtained from different strains or species of Brucellae (i.e. combining OPS extracted from different bacteria expressing “A” or “M” OPS, or combining OPS and OPS-protein complexes extracted from different bacteria). The OPS or OPS-protein complexes may also be obtained from a single strain expressing more than one OPS (e.g. from B. suis strain 145 which expresses “A”, “M” and possibly other OPSs). The vaccine according to the present invention overcomes the limitation of previously discovered B. abortus “A” OPS which only protects against species and strains of Brucella that had “A” OPS but not against others with different OPS.Type: GrantFiled: December 14, 2000Date of Patent: June 24, 2003Assignee: Her Majesty the Queen in right of Canada, as represented by the Minister of National Defence in her Brittanic Majesty's Government of the United Kingdom of Great Britain and Northern IrelandInventor: John W. Cherwonogrodzky
-
Patent number: 6576232Abstract: This invention provides mutant human interleukin 13 molecules showing varying specificity for the restricted (IL4 independent) IL13 receptor. The mutant hIL13 molecules include those made by substituting the amino acid residues that occur in the alpha-helix regions of native hIL13 with various other amino acid residues. Some of the mutants retain the ability to bind and cause signaling through IL13 receptors, while other mutants do not.Type: GrantFiled: October 5, 2000Date of Patent: June 10, 2003Assignee: The Penn State Research FoundationInventors: Waldemar Debinski, Jeffrey P. Thompson
-
Patent number: 6573003Abstract: The present invention includes methods for generating neutralizing antitoxin directed against clostridial toxins. In particular, the antitoxin directed against these toxins is produced in avian species using soluble recombinant clostridial toxin proteins. This avian antitoxin is designed so as to be orally administrable in therapeutic amounts and may be in any form (i.e., as a solid or in aqueous solution). These antitoxins are useful in the treatment of humans and other animals intoxicated with at least one bacterial toxin.Type: GrantFiled: November 16, 2001Date of Patent: June 3, 2003Assignee: Promega CorporationInventors: James A. Williams, John A. Kink
-
Patent number: 6558673Abstract: A complex of an immunogen and a support molecule, characterized in that the immunogen is coupled covalently to a support molecule, wherein the support molecule is a polypeptide fragment which is able to bind specifically to mammalian serum albumin is disclosed. The invention also relates to the use of such complexes to treat RSV infection, as well as vaccines derived from such complexes.Type: GrantFiled: July 27, 2000Date of Patent: May 6, 2003Assignee: Pierre Fabre MedicamentInventors: Hans Binz, Thien Ngoc Nguyen, Christine Andreoni, Ake Per Nygren, Stefan Stahl, Mathias Uhlen
-
Patent number: 6541007Abstract: A C-terminal pilin peptide vaccine for immunizing or treating a patient for infection by a Pseudomonas aeruginosa (PA) infection is disclosed. The peptide comprises the peptide identified as SEQ ID NOS. 3-6; and a carrier protein conjugated to the peptide. Also disclosed is a pilin peptide C-terminal PA pilin peptide having the amino acid sequence identified as SEQ ID NO:3, and analogs thereof having one of residues T, K, or A at position 130, D, T, or N at position 132, Q, A, or V at position 133, E, P, N, or A at position 135, Q, M, or K at position 136, and I, T, L, or R at position 138, excluding SEQ ID NOS: 1, 2, 9, 10, and 11, and the ability to cross-react with antibodies against the corresponding C-terminal peptides from PA strains PAK and PAO.Type: GrantFiled: June 30, 1999Date of Patent: April 1, 2003Assignee: The Governors of the University of AlbertaInventors: Robert S. Hodges, Randall T. Irvin, Paul J. Cachia
-
Patent number: 6531133Abstract: A chimeric protein comprising a Pseudomonas aeruginosa exotoxin (PE) moiety linked to a myelin basic protein (MBP) moiety is disclosed. The MBP moiety is selected from the group comprising: (a) MBP; (b) amino acids 69-88 of guinea-pig myelin basic protein or an antigenic portion thereof; (c) amino acids 84-102 of human myelin basic protein or an antigenic portion thereof; (d) amino acids 143-168 of human myelin basic protein or an antigenic portion thereof; and (e) an amino acid sequence in which one or more amino acids have been deleted, added, substituted or mutated in the amino acid sequences of (a), (b), (c) or (d), the modified sequence of (e) retaining at least 75% homology with the amino acid sequences of (a), (b), (c) or (d), respectively. Each of the MBP moieties of (b), (c) and (d) are linked to the PE moiety by a pentapeptide linker repeated 1-3 times. The chimeric protein is useful in treating autoimmune diseases, and especially multiple sclerosis.Type: GrantFiled: January 27, 1999Date of Patent: March 11, 2003Assignee: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Haya Lorberboum-Galski, Ida Steinberger, Eveline Beraud, Irina Marianovsky, Shai Yarkoni
-
Patent number: 6531131Abstract: A conjugate vaccine for Neisseria meningitidis comprising lipooligosaccharide which does not contain a lacto-N-tetraose antigen from which at least one primary O-linked fatty acid has been removed conjugated to an immunogenic carrier. The vaccine is useful for prevention of meningitis and septic shock in mammals.Type: GrantFiled: July 26, 2000Date of Patent: March 11, 2003Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Xin-Xing Gu, Chao-Ming Tsai
-
Patent number: 6514499Abstract: Compositions characterized by ADP-ribosyltransferase activity are useful in promoting prophylactic and/or therapeutic responses as are promoted by, e.g., pertussis toxin but directed against another target antigen (e.g., a cancer-related antigen) in a mammalian patient.Type: GrantFiled: February 22, 2000Date of Patent: February 4, 2003Inventor: Harvey R. Kaslow
-
Patent number: 6512094Abstract: Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate-specific protein, or mRNA encoding such a protein, in a sample are also provided.Type: GrantFiled: June 13, 2000Date of Patent: January 28, 2003Assignee: Corixa CorporationInventors: Jiangchun Xu, Davin C. Dillon, Jennifer L. Mitcham, Susan L. Harlocker, Yuqiu Jiang, Michael D. Kalos, Gary R. Fanger, Marc W. Retter, John A. Stolk, Craig H. Day, Thomas S. Vedvick, Darrick Carter, Samuel X. Li, Aijun Wang, Yasir A. W. Skeiky, William T. Hepler, Robert A. Henderson
-
Patent number: 6511666Abstract: This invention relates to the PrtR-PrtK cell surface protein of Porphyromonas gingivalis in particular a multimeric cell associated protein complex comprising the PrtR and PrtK proteins. There is provided a substantially purified antigenic complex for use in raising an antibody response directed against Porphyromonas gingivalis. The complex comprises at least one multimeric protein complex of arginine-specific and lysine-specific thiol endopeptidases each containing at least one adhesin domain. The complex has a molecular weight of greater than about 200 kDa. The invention also relates to pharmaceutical compositions and associated agents based on said complex for the detection, prevention and treatment of Periodontal disease associated with P. gingivalis.Type: GrantFiled: September 15, 1998Date of Patent: January 28, 2003Assignees: The University of Melbourne, Victorian Dairy Industry AuthorityInventors: Eric Charles Reynolds, Peter Singh Bhogal, Nada Slakeski
-
Patent number: 6503512Abstract: An immunomodulator complex for inhibiting intracellular replication of HIV retrovirus comprises cellular membrane fractions from at least one bacterial microorganism, and ribosomal RNA of that microorganism. The ribosomal RNA is covalently coupled to a glycoprotein amino acid sequence of type III collagen.Type: GrantFiled: January 30, 1995Date of Patent: January 7, 2003Inventor: Fernand Narbey Torossian
-
Patent number: 6500434Abstract: The present invention provides bacterial immunogenic agents for administration to humans and non-human animals to stimulate an immune response. It particularly relates to the vaccination of mammalian species with heteropolymeric protein complexes as a mechanism for stimulating production of antibodies that protect the vaccine recipient against infection by pathogenic bacterial species. In another aspect the invention provides antibodies against such proteins and protein complexes that may be used as diagnostics and/or as protective/treatment agents for pathogenic bacterial species. A novel vector for expressing the FimC-H complex at optimal levels is also disclosed.Type: GrantFiled: April 23, 1999Date of Patent: December 31, 2002Assignee: MedImmune, Inc.Inventors: Solomon Langermann, Scott J. Hultgren, Jerome S. Pinkner, Christine Gale Auguste
-
Patent number: 6488926Abstract: The invention provides a DNA construct comprising a DNA sequence encoding a fusion protein of the formula: TetC-(Z)a-Het, wherein: TetC is the C fragment of tetanus toxin, or a protein comprising the epitopes thereof; Het is a heterologous protein, Z is an amino acid, and a is zero or a positive integer, provided that (Z)a does not include the sequence Gly-Pro. The invention also provides replicable expression vectors containing the constructs, bacteria transformed with the constructs, the fusion proteins per se and vaccine compositions formed from the fusion proteins or attenuated bacteria expressing the fusion proteins.Type: GrantFiled: July 19, 1996Date of Patent: December 3, 2002Assignee: Medeva Holdings B.V.Inventors: Mohammed Anjam Khan, Carlos Estenio Hormaeche, Steven Neville Chatfield, Gordon Dougan
-
Patent number: 6476201Abstract: A continuous method for preparing proteosome-amphiphilic determinant vaccines for parenteral or mucosal administration using diafiltration or ultrafiltration technology. The amphiphilic determinants include lipopolysaccharides from gram negative bacteria, e.g. S. flexneri, P. shigelloides and S. sonnei. Proteosomes are obtained from group B type 2b meningococci. The active proteosome-amphiphilic determinant complexes (non-covalent complexes) of the vaccine are formed using diafiltration or ultrafiltration to remove the detergent under non-static conditions. The use of diafiltration or ultrafiltration decreases processing time and the opportunity for contamination and further permits the use of ambient temperature and efficient scale-up. In addition, the process permits the reliable and continuous monitoring of the dializate which enhances the efficiency of the entire process.Type: GrantFiled: July 27, 1998Date of Patent: November 5, 2002Assignees: ID Biomedical Corporation of Quebec, The United States of America as represented by the Secretary of the ArmyInventors: George H. Lowell, Wendell D. Zollinger, James F. Wood
-
Patent number: 6461615Abstract: The present invention relates to immunogenic complexes of heat shock proteins (hsp) noncovalently bound to exogenous antigenic molecules which when administered to an individual elicit specific immunological responses in the host. Methods of prevention and treatment of cancer and infectious disease are provided.Type: GrantFiled: April 7, 2000Date of Patent: October 8, 2002Assignee: Fordham UniversityInventor: Pramod K. Srivastava
-
Patent number: 6458367Abstract: The invention relates to a diagnostic test for the detection and identification of Mycobacterium species in biological specimens of human and animal origin. The test is based on the immunological detection of one or more antigens originating from Mycobacterium. To enable the detection of an antibody-antigen reaction, the antibodies specific for these antigens can be labelled with an enzyme or fluorescent dye or attached to latex particles or any other suitable label. The diagnostic test may be in a form of ELISA and may or may not require concentration of the Mycobacterium antigens prior to the actual test.Type: GrantFiled: May 4, 1999Date of Patent: October 1, 2002Assignee: Adcock Ingram LimitedInventors: Jan Adrianus Verschoor, Sandra Noel Bye
-
Patent number: 6451317Abstract: Disclosed is an H. influenzae type b polysaccharide-meningococcal outer membrane protein conjugate, pharmaceutical compositions thereof, and the use thereof to induce an immune response to H. influenzae in an animal.Type: GrantFiled: July 17, 1998Date of Patent: September 17, 2002Assignee: Baxter International Inc.Inventors: Milan S. Blake, Francis Michon, Peter C. Fusco, Iver Heron